Published • loading... • Updated
Cytokinetics (NASDAQ:CYTK) CEO Robert Blum Sells 7,500 Shares of Stock
Summary by insidertrades.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Cytokinetics (NASDAQ:CYTK) CEO Robert Blum Sells 7,500 Shares of Stock
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) CEO Robert Blum sold 7,500 shares of Cytokinetics stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $65.46, for a total value of $490,950.00. Following the completion of the transaction, the chief executive officer directly owned 278,544 shares of the company's stock, valued at approximately $18,233,490.24. This trade represents a 2.62% decrea…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
